Tanja Marinko (Author), Jure Dolenc (Author), Cvetka Bilban-Jakopin (Author)

Abstract

Background. Trastuzumab therapy given in combination with one of several chemotherapy regimens is currently considered the standard of care for the treatment of early-stage, human epidermal growth factor receptor-2 (HER2) -positive breast cancer. The treatment with trastuzumab is due to a significant impact on the survival part of the standard adjuvant treatment of patients with HER2-positive breast cancer. Patients treated with postoperative breast or chest wall irradiation receive trastuzumab concomitant with radiotherapy. In a small proportion of patients trastuzumab causes cardiotoxicity. Preclinical findings indicate a radiosensibilizing effect of trastuzumab in breast cancer cells, but it is not yet clear whether it radiosensibilizes cells of healthy tissues too.Conclusions. Special attention is required when left breast or left thoracic wall is irradiated in patient receiving trastuzumab, because long-term effects of the concurrent treatment with trastuzumab and radiotherapy are not yet known. In an era where more patients are surviving a diagnosis of breast cancer, better understanding and earlier detection of therapy-induced cardiac toxicity will be of paramount importance.

Keywords

radiotherapy;cardiotoxicity;trastuzumab;early breast cancer;

Data

Language: English
Year of publishing:
Typology: 1.01 - Original Scientific Article
Organization: OI - Institute of Oncology
Publisher: Association of Radiology and Oncology
UDC: 618.19-006-08
COBISS: 1686139 Link will open in a new window
ISSN: 1318-2099
Parent publication: Radiology and oncology
Views: 19
Downloads: 4
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: radioterapija;kardiotoksičnost;dojke;rak (medicina);
Type (COBISS): Not categorized
Pages: str. 105-112, I
Volume: ǂVol. ǂ48
Issue: ǂno. ǂ2
Chronology: Jun. 2014
DOI: 10.2478/raon-2013-0040
ID: 23403409